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Purpose:Yttrium-90 radioembolization (RE) is a locoregional therapy option for hepatocel-
lular carcinoma (HCC). Sorafenib is a multikinase inhibitor used in HCC that can potentially
affect the efficacy of RE by altering tumor vascularity or suppressing post-irradiation angio-
genesis. The safety and efficacy of sorafenib followed by RE has not been previously
reported.
Materials andMethods:Patients with HCC who received RE after sorafenib were included
in this retrospective review. Overall survival, toxicity, and maximal radiographic response
and necrosis criteria were examined.
Results: Ten patients (15 RE administrations) fit the inclusion criteria. All were Barcelona
Clinic Liver Cancer (BCLC) stage C. Median follow-up was 16.5 weeks. Median overall
survival and radiographic progression-free survival were 30 and 28 weeks, respectively.
Significant differences in overall survival were seen based on Child-Pugh class (p=0.002)
and radiographic response (p=0.009). Three patients had partial response, six had sta-
ble disease, and one had progressive disease. Grade 1 or 2 acute fatigue, anorexia, and
abdominal pain were common.Three patients had Grade 3 ascites in the setting of disease
progression. Two patients had Grade 3 biochemical toxicity. One patient was sufficiently
downstaged following RE and sorafenib to receive a partial hepatectomy.
Conclusion: Yttrium-90 RE in patients with HCC who have received sorafenib demon-
strate acceptable toxicity and rates of radiographic response. However, the overall survival
is lower than that reported in the literature on RE alone or sorafenib alone. This may be
due in part to more patients in this study having advanced disease compared to these
other study populations. Larger prospective studies are needed to determine whether the
combination of RE and sorafenib is superior to either therapy alone.
Keywords: yttrium-90, radioembolization,Y90, HCC, hepatocellular carcinoma, sorafenib, SIRT
INTRODUCTION
Hepatocellular carcinoma (HCC) has a global mortality of
~600,000 deaths per year (1). Most patients with HCC present
with advanced disease and are poor candidates for curative resec-
tion or liver transplantation (2). The options for locoregional
therapy to treat unresectable disease include ablative approaches
such as percutaneous alcohol injection or radiofrequency abla-
tion, conformal external beam radiation therapy or stereotactic
body radiation therapy, and multiple embolization techniques (3).
Llovet et al. demonstrated an overall survival benefit for bland arte-
rial embolization or transarterial chemoembolization (TACE) vs.
conservative treatment in a randomized trial (4).
Radioembolization (RE) with yttrium-90 (Y-90) microspheres
is another locoregional modality for HCC. Y-90 microspheres
are engineered to lodge in the microvasculature surrounding
liver tumors. The postulated method of action of Y-90 is that
liver malignancies draw most of their blood supply from the
hepatic arterial system while the normal liver parenchyma draws
most of its blood supply from the portal venous system, which
allows the microspheres to be preferentially targeted to tumors
rather than the normal liver. RE can be delivered with either
glass microspheres with an activity of ~2500 Bq per micros-
phere or resin microspheres with an activity of ~50 Bq per
microsphere (5).
Although glass microspheres are FDA-approved for treatment
of HCC and resin microspheres are FDA-approved for the treat-
ment of liver metastases from colorectal cancer, both appear to be
effective against HCC. A meta-analysis of HCC RE trials found
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a response rate of 89% for resin Y-90 microspheres, compared to
a rate of 78% for glass Y-90 microspheres (6). One large series
of HCC patients treated with glass Y-90 microspheres reported
an overall survival of 16.4 months (7), while the largest series of
patients treated with resin Y-90 microspheres reported an over-
all survival of 12.8 months (8). RE with glass (9, 10) or resin
(11) microspheres appears to have a long-term overall survival
that is similar to TACE in unmatched, non-randomized compar-
isons. One cohort comparison of patients treated with TACE vs.
glass microsphere RE reported that RE was superior in down-
staging patients with HCC from a United Network for Organ
Sharing (UNOS) T3 to UNOS T2, with a rate of 58% compared to
31% (12).
In addition to locoregional therapies, one systemic therapy
has recently been approved for the treatment of advanced HCC.
Sorafenib is a multikinase inhibitor affecting vascular endothe-
lial growth factor receptor (VEGF), platelet-derived growth factor
receptor, and Raf kinase. It has been shown to improve median
overall survival by 3 months in patients with advanced HCC in the
SHARP trial (13). Sorafenib disrupts tumor vasculature through
VEGF and hypoxia-inducible factor-1-alpha (HIF-1-alpha) inhi-
bition (14). Sorafenib may thus potentially decrease the efficacy
of RE by reducing the number of microspheres delivered to the
tumor. However, it could also theoretically increase the delivery
of microspheres to the tumor if radioembolization is performed
during the short period of tumor blood flow normalization that
follows the initiation of anti-angiogenic therapy (15). In addi-
tion, continued use of sorafenib after RE can potentially decrease
the induction of intratumor angiogenesis by sublethal irradia-
tion (16). The safety and efficacy of TACE followed in 4–7 days
by sorafenib has been demonstrated in the interim analysis of
the START trial (17), but the outcomes of RE combined with
sorafenib have not been well-reported in the literature. Thirty-
four patients who received sorafenib a median of 6 months after
RE were included in the series reported by Sangro et al. (8) but
their outcomes were not reported separately. The outcomes of
patients treated with sorafenib followed by RE have not been previ-
ously described. This study examines our institutional experience
with HCC patients who received sorafenib followed by Y-90 resin
microsphere RE.
MATERIALS AND METHODS
IRB approval was obtained for this retrospective review. The
records of all of the patients treated at our institution with Y-
90 transarterial RE for HCC were reviewed. The patients who
had started therapy with sorafenib prior to an administration
of RE were identified. Patients were staged according to the
Barcelona Clinic Liver Cancer (BCLC) classification system. RE
was delivered either in a single unilobar administration or in
two separate administrations directed to the right and left lobes
for patients requiring bilobar treatment. Patients who started
sorafenib between RE administrations for bilobar treatment were
included. Patients who were taking sorafenib were asked not to
take the drug the day before and the day of RE, and could resume
it the day after RE.
All patients were treated with resin Y-90 microspheres. The
details for the procedure can be found in the 2006 version
of the SIR-Spheres® product insert and in Kennedy et al. (5)
A pre-embolization angiogram was performed in all patients,
and vessels that supplied the gastrointestinal (GI) tract were coil
embolized. A 99m-technecium macroaggregated (99m-Tc MAA)
albumin scan was performed to calculate the lung shunt, and a
dose-reduction was applied to maintain a lung dose below 30 Gy.
The prescribed activity of microspheres to be delivered was calcu-
lated using body surface area (BSA) method, which incorporates
BSA, liver lobe volume, and percent tumor involvement of the lobe
into the dose calculation (5). If stasis was achieved prior to full
delivery of the prescribed dose of microspheres, the infusion was
stopped and the dose delivered was recorded. A post-embolization
Bremsstrahlung SPECT-CT scan was performed to confirm the
location of microsphere delivery.
Patients were generally seen in the interventional radiology
clinic 1–4 weeks after RE, and were subsequently followed by their
medical oncologists. Radiographic imaging (CT or MRI of the
abdomen) was obtained serially at the discretion of the treating
physician. Radiographic tumor response was evaluated using com-
bined Response Evaluation Criteria In Solid Tumors (RECIST) and
necrosis criteria as described by Keppke et al. (18). Only lesions in
the treated lobe of the liver were included in the RECIST evalu-
ation. Laboratory values that are examined in detail in this study
included serum alpha-fetoprotein (AFP) and serum total biliru-
bin, although other labs including complete blood count and liver
function tests were examined to assess biochemical toxicity. AFP
progression was defined as an increase of 20% above the previ-
ously measured value, and AFP response was defined as a decrease
of 20% below the previous value.
Toxicities were scored using the Common Toxicity Criteria for
Adverse Events version 4.0 (CTCAEv4). Constitutional toxicities
(fatigue, fever, chills, anorexia, sepsis, and weight loss), GI toxici-
ties (abdominal pain, nausea, vomiting, diarrhea, gastritis, hema-
tochezia, and pancreatitis), liver toxicities (portal hypertension,
portal vein thrombosis, and ascites), and lung toxicities (pneu-
monitis, pulmonary fibrosis, cough, and dyspnea) were included
in the assessment of clinical toxicity. If any increase over baseline
of the CTCAEv4 grade of a toxicity occurred during the patient’s
follow-up, the grade that the toxicity increased to was recorded
as the patient’s toxicity. Toxicities were conservatively attributed
to RE regardless of whether they could be attributed to be due to
RE, tumor progression, or cirrhosis. Acute toxicities were consid-
ered to have occurred within 90 days of the last RE. Toxicities that
occurred after any subsequent HCC-directed locoregional therapy
were censored. As late toxicities occurring >90 days post-RE are
less likely to be attributed to RE and more likely due to disease
progression or subsequent therapy, they were not recorded as per
Sangro et al. (8).
Overall survival and radiographic progression-free survival
(PFS) were calculated from time of RE for patients receiving unilo-
bar treatment, and from first RE in the patients who had bilobar
treatment. A patient met the endpoint for radiographic PFS if they
either died or had progressive disease (PD) on RECIST and necro-
sis criteria. Survival since time of diagnosis was calculated from
time of initial imaging (CT or MRI) or pathology definitive for
the diagnosis of HCC. Kaplan–Meier survival between groups was
compared using the logrank test. MedCalc® version 11.6.1.0 was
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used in the statistical analyses. Microsoft Excel 2010 was used for
graphing serum AFP and total bilirubin values following RE.
RESULTS
Ten patients were identified who fit our inclusion criteria. These
patients received RE between December 2009 and September 2012.
The patient characteristics are described in Table 1. Four patients
had disease confined to the liver and six patients had Stage IVA
or IVB disease at the time of RE. Seven patients had Child-Pugh
class A liver disease, and three patients had Child-Pugh class B liver
disease. All 10 patients were BCLC stage C.
Nine of the 10 patients were actively taking sorafenib within
2 weeks before at least one RE administration. Two patients initi-
ated their sorafenib therapy between their first and second RE. One
patient had stopped sorafenib therapy 5 months prior to the first
RE, and then received two cycles of a PARP inhibitor and temo-
zolomide before RE. The doses of sorafenib ranged from 200 mg
daily to 400 mg BID. The number of days sorafenib therapy was
initiated prior to RE was available for nine patients, with a median
of 43 days (range 9–905 days). Three patients had TACE prior to
RE, and one patient had received two partial hepatectomies prior
to RE. Three patients had portal vein thrombosis prior to RE.
The characteristics of the RE administrations are described in
Table 2. RE was performed in a single unilobar administration for
five patients. Bilobar treatment in two sessions was performed in
the remaining five patients. A total of 15 RE treatments were com-
pleted on the 10 patients. The time between the first and second
RE for the five patients receiving bilobar treatment ranged from 21
to 97 days. The lung shunts as calculated on the 99m-Tc MAA scan
were less than 10% for seven patients. The median total activity
delivered per RE was 27.8 mCi (range 10.6–50.6), and the median
dose to the target liver lesion(s) was 36.0 Gy (30.3–67.7 Gy). Two
of the 15 microsphere administrations had to be stopped due to
stasis, with 78 and 91% of the prescribed activity delivered to the
liver lobe in these two cases.
The median follow-up after the first administration of RE was
16.5 weeks (range 6–35 weeks). Five of the 10 patients had died by
the time of our analysis. The median overall survival (measured
from time of first RE and including patients censored because
they were alive at the time of analysis) in our patient population
was 30 weeks (range 6–42 weeks) (Figure 1). Of note, the over-
all survival when measured from time of diagnosis was 65 weeks
(range 15–192 weeks) and overall survival when measured from
date of initiation of sorafenib therapy was 61 weeks (range 8–
183 weeks). The overall survival was significantly correlated with
the patient’s Child-Pugh class (p= 0.002). The seven patients
who had Child-Pugh class A disease had a median overall sur-
vival of 42 weeks (range 11–42 weeks), while the three Child-Pugh
class B patients had a median overall survival of 12 weeks (range
6–17 weeks) (Figure 2). The median overall survival was not sig-
nificantly different based on portal vein thrombus vs. no portal
vein thrombus (p= 0.87), metastatic disease vs. no metastatic
disease (p= 0.13), prior locoregional therapy vs. no prior locore-
gional therapy (p= 0.47), age >65 vs. <65 (p= 0.73), Karnofsky
Performance Status >80 vs. ≤80 (p= 0.18), bilobar vs. unilo-
bar treatment (p= 0.87), or pre-RE AFP >400 vs. <400 ng/mL
(p= 0.49).
Table 1 | Patient characteristics.
PATIENT CHARACTERISTICS
Age (years) 63.5 (56–76)
Total patients (n) 10
Gender (n)
Male 8
Female 2
Child-pugh class (n)
A 7
B 3
BCLC stage (n)
C 10
Location of metastases (n)
No metastases 4
Lymph node metastases 5
Bone metastases 2
Peritoneal metastases 1
Lung metastases 1
Portal vein thrombosis (n) 3
Prior TACE (n) 3
Prior hepatectomy (n) 1
Sorafenib
Continued use peri-RE (n) 9
Sorafenib prior to RE only (n) 1
Duration of sorafenib use prior to RE (days) 43 (9–905)
The median and range or the n are shown. A total of 10 patients were treated
with RE.
Table 2 |Treatment characteristics.
TREATMENT CHARACTERISTICS
Total lobes treated (n) 15
Left 7
Right 8
Lobe volume (cc) 1314 (289–2421)
Tumor volume (cc) 231 (16–1576)
Tumor burden (%) 25 (2–70)
Total activity administered (mCi) 27.82 (10.62–50.64)
Dose to liver lobe (Gy) 35.95 (30.33–67.70)
Lung shunt (%) 5 (1–25)
Dose to lung (Gy) 3.46 (0.21–11.73)
The median and range or the n are shown. A total of 15 radioembolizations were
completed on 10 patients (n= 15).
The median radiographic follow-up was 17 weeks from the time
of first RE (range 3–35 weeks). The best radiographic response
achieved in the treated liver lobe(s) after RE and prior to the
initiation of other systemic or locoregional therapies was partial
response (PR) in three patients, stable disease (SD) in six patients,
and PD in one patient. The overall survival was significantly corre-
lated with RECIST and necrosis response (p= 0.009) (Figure 3).
The patient who had PD died 6 weeks after his unilobar RE. The
median overall survival was 30 weeks (range 5–28 weeks) for the
six patients with SD, and it was not reached for the three patients
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FIGURE 1 | Kaplan–Meier overall survival. Median overall survival
(measured from time of first RE and including patients censored because
they were alive at the time of analysis) for the entire series was 30 weeks
(range 6–42 weeks).
FIGURE 2 | Kaplan–Meier overall survival by Child-Pugh class. The
median overall survival was 42 weeks (range 11–42 weeks) for Child-Pugh
class A patients and 12 weeks (range 6–17 weeks) for Child-Pugh class B
patients (p=0.002).
with PR (range 6–35 weeks). The median radiographic PFS for all
10 patients was 28 weeks (range 3–42 weeks) (Figure 4).
Follow-up serum AFP values were available for 9 out of our
10 patients, with a median interval from the first RE to AFP mea-
surement of 60 days (range 8–154 days). The follow-up AFPs for
each patient are shown in Figure 5. Of the three patients who had
an elevated serum AFP of above 400 ng/mL before their first RE,
all three had a >20% response in AFP levels at the first follow-
up measurement. The follow-up serum total bilirubin values are
shown in Figure 6. In the acute setting (<90 days post-RE), 9
of 10 patients had stable or downward trends in total bilirubin
FIGURE 3 | Kaplan–Meier overall survival by radiographic response.
Median radiographic follow-up was 17 weeks (range 3–35 weeks). The
median overall survival was 6 weeks for the one patient with PD, 30 weeks
(range 5–28 weeks) for the six with SD, and it was not reached for the three
patients with PR (range 6–35 weeks) (p= 0.009).
FIGURE 4 | Kaplan–Meier radiographic progression-free survival.
Median radiographic progression-free survival of the entire series was
28 weeks (range 3–42 weeks).
following RE. The rising trends in total bilirubin in patients b and
c occurred in the setting of radiographically documented disease
progression. Patient f had a temporary spike in the total bilirubin
value 18 weeks after RE at the time of a left hepatectomy.
The acute clinical toxicities experienced by the patients in the
study after RE are listed in Table 3. The rate of overall (consti-
tutional, GI, liver, lung) acute toxicity was 70% (Table 3). Three
patients experienced Grade 3 clinical toxicity, with one patient
experiencing Grade 3 ascites in the setting of clear radiographic
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FIGURE 5 | Alpha-fetoprotein (AFP) trend per patient. Patients a, f, and h had an elevated pre-RE AFP of >400 ng/mL, all three had a AFP response to RE.
FIGURE 6 |Total bilirubin trend per patient. The spike in total bilirubin seen in patient f was secondary to a resection of the remaining tumor mass 18 weeks
after RE, patients b and c had total bilirubin rises in the setting of disease progression.
progression of his liver disease. Two patients experienced Grade 3
ascites prior to scans showing increased liver tumor size that did
not meet the RECIST and necrosis criteria for disease progression,
and one of those patients also had Grade 3 anorexia and abdom-
inal pain. Common Grade 1–2 toxicities included fatigue (four
patients), anorexia (three patients), weight loss (three patients),
and abdominal pain, nausea, vomiting, and diarrhea (each two
patients). One patient had Grade 2 portal hypertension, and one
patient had Grade 1 cough.
The acute biochemical toxicities are shown in Table 4. One
patient had a Grade 3 elevation in total bilirubin in the setting of
disease progression, and the other patient had a Grade 3 increase in
AST following his second RE. In addition, five patients had Grade
1–2 biochemical liver toxicity, and eight patients had Grade 1–2
biochemical hematologic toxicity.
One patient was able to receive a left hepatectomy following
RE and sorafenib. This patient was a 60-year-old male with cir-
rhosis who was diagnosed with HCC in segment IV. He did not
meet Milan criteria for liver transplantation due to the 6.7 cm size
of the tumor and questionable vascular invasion (Figure 7). He
also had non-specific mediastinal lymph node enlargement and a
3 mm right lung nodule at presentation that were suspicious for
metastatic disease. He had a left portal vein thrombosis, making
him ineligible for TACE. He was Child-Pugh class A, BCLC stage
C. He was started on sorafenib at 400 mg BID, and RE with resin
Y-90 microspheres was delivered through the left hepatic artery
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Table 3 | Acute clinical toxicities.
CTCAE Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
HIGHEST GRADE OFACUTE CLINICALTOXICITY (n=10)
Constitutional 4 3 2 1 0 0
Fatigue 6 2 2 0 0 0
Fever 10 0 0 0 0 0
Chills 10 0 0 0 0 0
Anorexia 6 1 2 1 0 0
Sepsis 10 0 0 0 0 0
Weight loss 7 1 2 0 0 0
GI 5 2 2 1 0 0
Abdominal pain 7 2 0 1 0 0
Nausea 8 0 2 0 0 0
Vomiting 8 1 1 0 0 0
Diarrhea 8 2 0 0 0 0
Gastritis 10 0 0 0 0 0
Hematochezia 10 0 0 0 0 0
Pancreatitis 10 0 0 0 0 0
Liver 7 0 0 3 0 0
Portal hypertension 9 0 1 0 0 0
Portal vein thrombosis 10 0 0 0 0 0
Ascites 7 0 0 3 0 0
Lung 9 1 0 0 0 0
Pneumonitis 10 0 0 0 0 0
Pulmonary fibrosis 10 0 0 0 0 0
Cough 9 1 0 0 0 0
Dyspnea 10 0 0 0 0 0
Overall 3 3 1 3 0 0
The number of patients with their highest CTCAEv.4 Grade toxicity is shown by category. There were no Grade 4 or 5 toxicities.
Table 4 | Acute biochemical toxicities.
CTCAE Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
HIGHEST GRADE OFACUTE BIOCHEMICALTOXICITY (n=10)
Liver 3 4 1 2 0 0
ALT 5 4 1 0 0 0
AST 9 0 0 1 0 0
Alk Phos 5 4 1 0 0 0
T. Bili 7 2 0 1 0 0
Hematologic 2 2 6 0 0 0
WBC 7 1 2 0 0 0
Hgb 5 2 3 0 0 0
Plt 5 4 1 0 0 0
Overall 1 2 5 2 0 0
The number of patients with their highest CTCAEv.4 Grade toxicity is shown
by category. There were no Grade 4 or 5 toxicities. ALT, alanine aminotrans-
ferase; AST, aspartate aminotransferase; Alk Phos, alkaline phosphatase; T. Bili,
total bilirubin;WBC, white blood cell; Hgb, hemoglobin; Plt, platelet.
10 days later. The activity administered was 48.5 mCi, giving a cal-
culated dose of 44.5 Gy to the liver lesion. He experienced mild
short-term fatigue, anorexia, and diarrhea following RE. Follow-
up imaging from 7 weeks post-RE and 15 weeks post-RE showed
significant tumor response (Figures 8 and 9), with well-preserved
liver function. He also had an 83% decrease in his serum AFP
from 5675 to 957 ng/mL following RE. His sorafenib was stopped
2 weeks prior to the extended left hepatectomy (Figure 10) that
the patient received 18 weeks after RE.
On surgical pathology, 90% of the resected mass was necrotic
(Figure 11). The Y-90 microspheres were more densely localized
to the tumor (Figure 12) compared to the uninvolved, cirrhotic
liver (Figure 13). Unfortunately, after surgery the patient devel-
oped ascites due to liver decompensation, and 2 months after
surgery his enlarged subcarinal lymph node was biopsied and
showed metastatic HCC. His sorafenib was re-started 4 weeks
post-resection. At his last follow-up 8 months after RE, the patient
remains on sorafenib and is free of disease in his liver.
DISCUSSION
In our institutional experience, sorafenib use does not appear
to affect the technical feasibility of RE. The procedural aspects
of RE, including angiography, coil embolization of the collat-
eral vessels feeding the GI tract, 99m-Tc MAA calculation of
the lung shunt, and microsphere delivery were accomplished in
these patients without unexpected difficulty, and the prescribed
doses were delivered without stasis for the majority of RE admin-
istrations. Pathologic examination of one resected specimen sug-
gested that deposition of the microspheres is preferentially directed
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FIGURE 7 | T1 MRI with early phase contrast. Pre-radioembolization.
FIGURE 8 | T1 MRI with early phase contrast. Seven weeks post-RE.
toward the tumor vasculature rather than the liver parenchyma as
expected, but a full dosimetric study of the pathologic specimen
could not be performed given the limited amount of tissue that
was preserved.
The median overall survival from time of RE was 30 weeks
(7 months), compared to a survival since time of diagnosis of
65 weeks (15 months). The overall survival from time of RE for our
series is lower than the overall survivals of 12.8 and 16.4 months
reported in larger series of patients treated with RE alone (7, 8).
This could be due in part to our patients receiving RE late in the
course of their disease. In our practice, patients tended to receive
other therapies before initiating RE, which is reflected in the differ-
ence between the survival from time of diagnosis and the survival
from time of RE. In addition, the patients in our study were all
FIGURE 9 | T1 MRI with early phase contrast. Fifteen weeks post-RE.
FIGURE 10 | T1 MRI with early phase contrast. Status-post extended left
hepatectomy, performed 6 months post-RE.
BCLC stage C, and our median overall survival from the time of
RE is comparable to the 7.3 months reported for BCLC stage C
patients in Salem et al. (19). The difference in overall survival
between Child-Pugh class A and B patients that was seen in Hil-
gard et al. (7), Sangro et al. (8), and Salem et al. (19) were also
noted in our study. The survival disparity between Child-Pugh
class A and Child-Pugh class B suggests that RE could potentially
be more effective when performed earlier in the natural course
of HCC.
The 12 week overall survival in our three Child-Pugh class B
patients is concerning. This low survival is likely due to rapid dis-
ease progression, rather than toxicity due to RE and sorafenib. Of
these patients, one was on tigatuzumab and sorafenib as part of a
clinical trial and stopped tigatuzumab but continued on sorafenib
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FIGURE 11 | Micrographs of hematoxylin and eosin-stained sections of
the resected liver. Necrotic tumor with microspheres at 40×magnification.
FIGURE 12 | Micrographs of hematoxylin and eosin-stained sections of
the resected liver. Viable tumor cells with a microsphere at 200×
magnification.
2 weeks prior to RE due to disease progression. This patient con-
tinued to have PD 1 month after completing sequential RE and
required additional local therapy with TACE. This patient even-
tually opted for hospice care and passed away 17.3 weeks after
initiation of RE. Another Child-Pugh B patient who had a throm-
bus in the left portal vein prior to RE had disease progression in the
untreated lobe and developed a thrombus in the left hepatic vein
1 month after initiation of RE. This patient elected for hospice care
and survived 6.4 weeks following RE. The third Child-Pugh class
B patient developed progressive ascites as well as a partial small
bowel obstruction of unknown etiology 10 weeks after initiation
of RE. This patient elected for hospice care after discharge and
passed away 11.7 weeks after RE. Based on the experience of these
three Child-Pugh class B patients, RE may not provide benefit
FIGURE 13 | Micrographs of hematoxylin and eosin-stained sections of
the resected liver. Viable cirrhotic liver tissue with no microspheres at
100× magnification, typical of the patient’s liver that wasn’t involved with
tumor.
in patients with rapid disease progression, and could potentially
contribute to their clinical deterioration. Therefore, caution may
be warranted in employing RE for BCLC C, Child-Pugh class B
patients who are on sorafenib, particularly if their expectation of
a response is low.
When compared to treatment with sorafenib alone, the median
overall survival from time of RE of 30 weeks (7 months) for our
series is lower than the 10.7 months reported in the arm receiving
sorafenib in the SHARP trial (13). However, all of the patients
included in our series had BCLC stage C disease, vs. 82% of the
patients in the experimental arm of the SHARP trial, and 30% of
our patients were Child-Pugh class B, vs. 5% in the SHARP trial
(13). In addition, overall survival was measured from date of first
RE in this study, while it was measured from date of randomization
in the SHARP trial. However, the survival in our study from the
date of diagnosis is 65 weeks (15 months), and the survival in our
study from the date of initiation of sorafenib therapy was 61 weeks
(14 months), which compare more favorably to the 10.7 months
overall survival reported in the SHARP trial (13).
The radiographic response in our series is comparable to other
published results, with 30% having a PR, 60% SD, and 10% PD.
Although the meta-analysis by Vente et al. reported an 89 and
78% response rate for resin and glass microspheres respectively,
the criteria for response was not well-reported for many of the
studies included in the paper (6). The only study in the meta-
analysis that reported RECIST response for HCC included only
four patients, with 25% PR, 50% SD, and 25% PD (20). Since
then, Hilgard et al. have reported that 6% of their cohort had a
complete response (CR), 35% PR, 48% SD, and 10% PD by the
RECIST and necrosis criteria by 2 months after RE (7). Salem et al.
reported a European Association for the Study of the Liver (EASL)
response rate of 44% for their BCLC C patients (19). In addition,
the radiographic PFS of 28 weeks (6.4 months) for our series is
comparable to the 6.0 months time-to-progression reported for
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BCLC C patients in Salem et al. (19). The 100% AFP response rate
in the three patients with pre-treatment AFPs above 400 mg/mL
and the ability of one patient to be sufficiently downstaged to have
a partial liver resection is promising.
Another possible explanation for lower survival in this study
may be due to increase in toxicity. The overall rates of fatigue
(54.5–61%), abdominal pain (23–56%), nausea/vomiting (20–
32%), anorexia (15%), and fever (3–12.3%) that are reported in
the larger series on RE for HCC are comparable to the rates seen
in our study (7, 8, 19). However, the rates of Grade 3 clinical tox-
icity in our study are higher than those reported in these other
studies. All of the acute Grade 3 toxicities in our study occurred
in the setting of disease progression, which confounds the assess-
ment of whether radiation-induced liver disease contributed to
the liver toxicity seen in these patients. All of our patients with
Grade 3 acute clinical toxicity experienced Grade 3 ascites, which
was not a toxicity examined by Salem et al. or Sangro et al. (8,
19). Hilgard et al. reported a low rate of 3% for Grade 1–2 ascites
and no Grade 3 ascites, but the study only included events that
occurred within 30 days of RE in their toxicity analysis (7). In gen-
eral the patients treated in these studies had a lower BCLC stage
than the patients in our series, and were thus less likely to develop
ascites caused by pre-RE liver dysfunction. The observation that
the post-RE levels of serum total bilirubin in our series are stable
outside the setting of disease progression or liver resection argues
against an increased rate of radiation-induced liver disease. The
40% rate of Grade 2 anemia and thrombocytopenia seen in our
study is higher than the 6–15% rate reported in Hilgard et al. and
this is most likely related to the continued use of sorafenib after
RE (7). There were no Grade 3 or higher hematologic toxicities in
our study, compared to the 4% rate of Grade 3 or 4 thrombocy-
topenia observed in the arm that received sorafenib in the SHARP
trial (13).
This study is limited by the small number of patients and
the relatively short median follow-up, but the study suggests that
combining sorafenib and RE is clinically feasible. Additionally,
the ability of one patient in this study to be sufficiently down-
staged to have a partial liver resection after sorafenib and RE
is promising. However, the shorter survival times in this study,
when compared to the survivals reported in the literature on RE
alone or sorafenib alone, raises important questions on the safety
of combining RE and sorafenib. While the shorter survivals in
this study may be explained by patients being further along in
their disease course compared to the study populations in the
literature, prospective studies are needed to determine whether
the combination of RE and sorafenib is superior to either ther-
apy alone. An ideal study would be a randomized controlled trial
that compares sorafenib alone, RE alone, and RE+sorafenib. Nev-
ertheless, it may be difficult to accrue enough patients to give
such a study sufficient power. Further insight into the number
of patients needed to give sufficient power to such a three-
arm study may be derived from the ongoing STOP-HCC and
SORAMIC trials, which are currently comparing treatment with
sorafenib alone vs. RE followed by sorafenib. However, these tri-
als do not employ the concurrent use of sorafenib and RE, and
the optimal timing of RE and sorafenib therapy remains an open
question.
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